Latest in Cardiology from ACC.org

• The Case For Earlier LDL Cholesterol Lowering: Supporting Lifelong Healthy Vascular Aging
  Atherosclerosis begins early and progresses silently. Patients requiring secondary prevention have already accumulated decades of low-density lipoprotein cholesterol (LDL-C) exposure resulting in some potentially irreversible arterial aging and injury.
• FDA Update: Abiomed Updates Use Instructions to Address Heart Pump Issue
  The U.S. Food and Drug Administration (FDA) has issued an Early Alert, sharing that Abiomed has updated use instructions for all Impella RP with SmartAssist and Impella RP Flex with SmartAssist devices.
• Eagle’s Eye View: Smartwatch Screening Improved AFib Detection
  In this week’s View, Dr. Eagle looks at the ORBITA-2 trial and how percutaneous coronary intervention (PCI) may lead to greater symptom relief in older adults.
• ACC Streamlines Cardiac Accreditation For International Hospital Systems
  ACC’s Global Quality Solutions program now offers international hospitals and health systems a new pathway to achieving ACC Accreditation. Previously, sites needed to submit data through the associated NCDR registry to be eligible for accreditation.
• EMPA-ICD Subanalysis: Is Sex a Factor in Effect of Empagliflozin in Patients With T2D?
  In patients with type 2 diabetes (T2D) treated with ICDs, the arrhythmic effect of empagliflozin appears more pronounced in men than in women, according to a subanalysis of the EMPA-ICD trial published Jan. 22 in JACC: Asia.